Ureteral stents are essential tools for maintaining kidney function and relieving obstructions, but they carry a hidden risk: they can become blocked. When a stent fails, it can trigger hydronephrosis—a condition where urine backs up into the kidney, increasing intrarenal pressure and potentially causing permanent organ damage.
Currently, clinicians detect these complications using intermittent imaging such as X-rays, CT scans, or ultrasound. However, these methods provide only a snapshot in time and are not suited for the continuous, remote monitoring required to catch pressure spikes before they lead to renal failure. A new approach from a University of British Columbia-led team aims to change this by introducing a wireless ureteral stent sleeve enables early detection of hydronephrosis without requiring a redesign of the stents themselves.
The technology, detailed in a 2026 study published in Microsystems & Nanoengineering, introduces “UroSleeve.” Unlike previous “smart stent” attempts that required modifying the stent’s internal structure—which complicates manufacturing and regulatory approval—UroSleeve is a modular add-on. It slides over standard double-J ureteral stents, preserving their existing mechanics while adding a layer of real-time diagnostic capability.
By integrating a microfabricated capacitive pressure sensor with a flexible spiral antenna, the system allows doctors to track kidney pressure through near-field inductive coupling. Because the device is passive, it requires no onboard battery, significantly reducing the risk of device failure or toxicity within the urinary tract.
Engineering a Passive Monitoring System
The technical hurdle in monitoring intrarenal pressure has long been the balance between sensitivity and biocompatibility. Traditional sensors often require bulky power sources or rigid materials that interfere with the flexibility of the stent. UroSleeve overcomes this by utilizing a flexible printed-circuit-board (PCB) spiral antenna and a specialized touch-mode capacitive pressure sensor enabled by a Tesla-valve design.
This configuration creates a passive LC tank circuit. When an external antenna reads the device, the system tracks pressure increases by monitoring downward shifts in resonant frequency. This means the device doesn’t “transmit” in the traditional sense; rather, its resonant properties change based on the pressure exerted on the sleeve, which can then be read from outside the body.
In an ex vivo model using a swine kidney and ureter, the researchers simulated hydronephrosis by increasing the fluid pressure in the renal pelvis. The system demonstrated high precision, with a baseline phase-dip frequency of 15.234 MHz at 8.5 mmHg. The sensitivity was measured at −5.3 ± 0.74 kHz/mmHg, remaining effective across a range of up to 56 mmHg.
| Metric | Value/Result |
|---|---|
| Baseline Frequency | 15.234 MHz at 8.5 mmHg |
| Pressure Sensitivity | −5.3 ± 0.74 kHz/mmHg |
| Maximum Tested Range | Up to 56 mmHg |
| Power Source | Passive (No battery) |
Clinical Implications for Kidney Care
The shift from episodic imaging to continuous monitoring could fundamentally change the management of patients recovering from kidney stones, strictures, or urological surgeries. For these patients, a blocked stent is a “silent” complication; by the time a patient feels symptomatic, the kidney may have already suffered significant pressure-induced damage.
The modular nature of the wireless ureteral stent sleeve means it can be adapted to various commercial stent platforms. This versatility eases the path toward regulatory adoption, as the sleeve does not change the safety profile of the underlying stent that has already been FDA-approved or clinically validated.
If translated to clinical use, the technology could provide several key benefits:
- Earlier Intervention: Detecting obstruction in real-time allows for the timely exchange of stents before renal function is impaired.
- Reduced Radiation: A decrease in reliance on repeated CT scans and X-rays for monitoring.
- Personalized Follow-up: Tailoring the timing of stent removal or replacement based on a patient’s specific physiological data rather than a generic schedule.
Path to Clinical Translation
While the ex vivo results are promising, the researchers acknowledge that the technology is currently a proof of concept. The transition from a laboratory swine model to human patients requires a rigorous set of validation steps. The team has identified several critical areas for future research, including long-term reliability studies to ensure the sleeve does not degrade or migrate within the ureter.
Biocompatibility testing is also paramount, as the materials used in the flexible PCB and the sensor must withstand the harsh, chemically active environment of the urinary tract over extended periods. The team intends to refine the readout strategies to ensure that external signals can be captured accurately through the layers of human tissue and muscle.
The ultimate goal is a framework for “smarter” urological monitoring that reduces the healthcare burden associated with delayed detection of hydronephrosis and improves overall patient safety.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next phase of development will focus on in vivo studies to validate the performance of UroSleeve under actual physiological conditions, which will determine the device’s readiness for human clinical trials.
We would love to hear your thoughts on the intersection of wearable tech and internal medicine. Share this story or leave a comment below.
